Walden Biosciences
Cambridge, United States· Est. 2019
Walden is advancing a pipeline of novel, disease-modifying therapies that directly target the kidney.
Private Company
Total funding raised: $129M
About
Walden is advancing a pipeline of novel, disease-modifying therapies that directly target the kidney.
AntibodiesBiologicsSmall Molecules
Funding History
3Total raised:$129M
Series B$73MMay 15, 2023
Series A$51MOct 15, 2021
Seed$5MSep 15, 2020